View in EDS

Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.

Saved in:
Bibliographic Details
Title: Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.
Authors: Moore, M.1 malcolm.moore@bccancer.bc.ca, Gill, S.1, Asmis, T.2, Berry, S.3, Burkes, R.4, Zbuk, K.5, Alcindor, T.6, Jeyakumar, A.7, Chan, T.8, Rao, S.9, Spratlin, J.10, Tang, P. A.11, Rothenstein, J.12, Chan, E.13, Bendell, J.14, Kudrik, F.15, Kauh, J.16, Tang, S.16, Gao, L.16, Kambhampati, S. R. P.16
Source: Annals of Oncology. Dec2016, Vol. 27 Issue 12, p2216-2224. 9p. 2 Diagrams, 3 Charts, 1 Graph.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdw412